CA3118293A1 - Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds - Google Patents
Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds Download PDFInfo
- Publication number
- CA3118293A1 CA3118293A1 CA3118293A CA3118293A CA3118293A1 CA 3118293 A1 CA3118293 A1 CA 3118293A1 CA 3118293 A CA3118293 A CA 3118293A CA 3118293 A CA3118293 A CA 3118293A CA 3118293 A1 CA3118293 A1 CA 3118293A1
- Authority
- CA
- Canada
- Prior art keywords
- fluoro
- compound
- pharmaceutically acceptable
- acceptable salt
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752278P | 2018-10-29 | 2018-10-29 | |
| US62/752,278 | 2018-10-29 | ||
| PCT/US2019/058297 WO2020092208A1 (en) | 2018-10-29 | 2019-10-28 | Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3118293A1 true CA3118293A1 (en) | 2020-05-07 |
Family
ID=68841171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3118293A Pending CA3118293A1 (en) | 2018-10-29 | 2019-10-28 | Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US11034693B2 (https=) |
| EP (3) | EP4736855A2 (https=) |
| JP (3) | JP7447110B2 (https=) |
| KR (2) | KR102797129B1 (https=) |
| CN (3) | CN113056465B (https=) |
| AR (1) | AR116880A1 (https=) |
| AU (2) | AU2019373206B2 (https=) |
| BR (1) | BR112021008077A2 (https=) |
| CA (1) | CA3118293A1 (https=) |
| CL (1) | CL2021001083A1 (https=) |
| CO (1) | CO2021005540A2 (https=) |
| DK (2) | DK3873904T3 (https=) |
| EA (1) | EA202191152A1 (https=) |
| ES (1) | ES2986923T3 (https=) |
| FI (2) | FI3873904T3 (https=) |
| HR (2) | HRP20241065T1 (https=) |
| HU (1) | HUE068265T2 (https=) |
| IL (2) | IL325304A (https=) |
| LT (2) | LT3873904T (https=) |
| MX (2) | MX2021004955A (https=) |
| PE (1) | PE20211780A1 (https=) |
| PL (1) | PL3873904T3 (https=) |
| PT (1) | PT3873904T (https=) |
| RS (1) | RS65963B1 (https=) |
| SG (1) | SG11202104218SA (https=) |
| SI (2) | SI3873904T1 (https=) |
| SM (1) | SMT202400358T1 (https=) |
| TW (3) | TW202521537A (https=) |
| WO (1) | WO2020092208A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3088347A1 (en) | 2018-01-17 | 2019-07-25 | Glaxosmithkline Intellectual Property Development Limited | Pi4kiii.beta. inhibitors |
| EA202191152A1 (ru) | 2018-10-29 | 2022-01-19 | Миокардиа, Инк. | Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| CN114149423B (zh) * | 2020-09-08 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114456163B (zh) * | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| WO2022105852A1 (zh) | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| CN119053591A (zh) | 2022-05-20 | 2024-11-29 | 江苏恒瑞医药股份有限公司 | 一种三嗪二酮类衍生物的晶型及制备方法 |
| IL318417A (en) | 2022-07-29 | 2025-03-01 | Myokardia Inc | Crystalline forms of (6s,7s)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2h-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2 ,3-d]pyrimidine-2,4(lh,3h)-dione |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU725689B2 (en) | 1995-06-07 | 2000-10-19 | G.D. Searle & Co. | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure |
| GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9663516B2 (en) * | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| EA202191152A1 (ru) | 2018-10-29 | 2022-01-19 | Миокардиа, Инк. | Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона |
-
2019
- 2019-10-28 EA EA202191152A patent/EA202191152A1/ru unknown
- 2019-10-28 HR HRP20241065TT patent/HRP20241065T1/hr unknown
- 2019-10-28 PE PE2021000596A patent/PE20211780A1/es unknown
- 2019-10-28 TW TW114104487A patent/TW202521537A/zh unknown
- 2019-10-28 SI SI201930816T patent/SI3873904T1/sl unknown
- 2019-10-28 CN CN201980071171.4A patent/CN113056465B/zh active Active
- 2019-10-28 KR KR1020217016041A patent/KR102797129B1/ko active Active
- 2019-10-28 AU AU2019373206A patent/AU2019373206B2/en active Active
- 2019-10-28 HR HRP20260161TT patent/HRP20260161T1/hr unknown
- 2019-10-28 US US16/665,897 patent/US11034693B2/en active Active
- 2019-10-28 CN CN202510034970.1A patent/CN119977963A/zh active Pending
- 2019-10-28 DK DK19817827.9T patent/DK3873904T3/da active
- 2019-10-28 FI FIEP19817827.9T patent/FI3873904T3/fi active
- 2019-10-28 PT PT198178279T patent/PT3873904T/pt unknown
- 2019-10-28 RS RS20241031A patent/RS65963B1/sr unknown
- 2019-10-28 SG SG11202104218SA patent/SG11202104218SA/en unknown
- 2019-10-28 JP JP2021523927A patent/JP7447110B2/ja active Active
- 2019-10-28 TW TW113107743A patent/TWI876902B/zh active
- 2019-10-28 WO PCT/US2019/058297 patent/WO2020092208A1/en not_active Ceased
- 2019-10-28 LT LTEPPCT/US2019/058297T patent/LT3873904T/lt unknown
- 2019-10-28 AR ARP190103118A patent/AR116880A1/es unknown
- 2019-10-28 ES ES19817827T patent/ES2986923T3/es active Active
- 2019-10-28 KR KR1020257012076A patent/KR20250053228A/ko active Pending
- 2019-10-28 HU HUE19817827A patent/HUE068265T2/hu unknown
- 2019-10-28 CN CN202510034967.XA patent/CN119977962A/zh active Pending
- 2019-10-28 LT LTEP24186221.8T patent/LT4464321T/lt unknown
- 2019-10-28 SM SM20240358T patent/SMT202400358T1/it unknown
- 2019-10-28 MX MX2021004955A patent/MX2021004955A/es unknown
- 2019-10-28 EP EP26150390.8A patent/EP4736855A2/en active Pending
- 2019-10-28 TW TW108138912A patent/TWI837202B/zh active
- 2019-10-28 EP EP19817827.9A patent/EP3873904B1/en active Active
- 2019-10-28 IL IL325304A patent/IL325304A/en unknown
- 2019-10-28 FI FIEP24186221.8T patent/FI4464321T3/fi active
- 2019-10-28 EP EP24186221.8A patent/EP4464321B1/en active Active
- 2019-10-28 BR BR112021008077-5A patent/BR112021008077A2/pt unknown
- 2019-10-28 PL PL19817827.9T patent/PL3873904T3/pl unknown
- 2019-10-28 CA CA3118293A patent/CA3118293A1/en active Pending
- 2019-10-28 SI SI201931020T patent/SI4464321T1/sl unknown
- 2019-10-28 DK DK24186221.8T patent/DK4464321T3/da active
-
2021
- 2021-04-27 CL CL2021001083A patent/CL2021001083A1/es unknown
- 2021-04-28 CO CONC2021/0005540A patent/CO2021005540A2/es unknown
- 2021-04-28 IL IL282740A patent/IL282740B1/en unknown
- 2021-04-29 MX MX2024004892A patent/MX2024004892A/es unknown
- 2021-12-17 US US17/554,353 patent/US20220106314A1/en not_active Abandoned
-
2022
- 2022-06-30 US US17/854,398 patent/US20220340569A1/en not_active Abandoned
-
2023
- 2023-08-01 US US18/228,911 patent/US12344607B2/en active Active
-
2024
- 2024-02-28 JP JP2024028058A patent/JP7703716B2/ja active Active
-
2025
- 2025-02-13 AU AU2025200975A patent/AU2025200975A1/en active Pending
- 2025-05-27 US US19/219,406 patent/US20250282779A1/en active Pending
- 2025-06-25 JP JP2025106973A patent/JP2025138748A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12344607B2 (en) | Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases | |
| US20230158027A1 (en) | Methods of treatment with myosin modulator | |
| HK40119292A (en) | Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds | |
| HK40061965A (en) | Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds | |
| HK40061965B (en) | Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds | |
| JP2007538054A (ja) | 肥満および関係する病気の予防または治療のためのｎ−スルファモイル−ｎ′−アリールピペラジンを含有する薬剤 | |
| EA053114B1 (ru) | Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона | |
| EA050645B1 (ru) | Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона | |
| EA046692B1 (ru) | Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона | |
| WO2009153261A1 (en) | HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | |
| TW201028390A (en) | Flavononol renin inhibitor compounds and methods of use thereof | |
| KR20070022322A (ko) | Ｎ설파모일ｎ′아릴피페라진을 함유한 비만 및 관련된상태의 예방 또는 치료용 의약 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220927 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240711 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240906 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241002 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250203 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250212 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250630 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251029 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260105 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260105 |